SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...
In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...
In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...
Late Wednesday, a U.S. Food and Drug Administration panel recommended that Edwards Lifesciences (NYSE:EV) transcatheter aortic valve replacement procedure be approved for patients with high risk to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results